FiercePharmaAsia—Pfizer, China-India alliance, Sinovant and more by Angus Liu Friday, July 20, 2018 Pfizer halts production at a legacy Hospira plant; China works to offer Indian drugmakers streamlined access; Roivant's Sinovant debuts with 11 assets.
Pfizer, Astellas’ Xtandi grabs key nod in nonmetastatic cancer by Tracy Staton Monday, July 16, 2018 Pfizer and Astellas’ prostate cancer med Xtandi nabbed broader FDA approval, setting it up for a head-to-head fight with J&J’s Erleada.
No need for a megamerger, Pfizer CEO says. Our pipeline's got it by Eric Sagonowsky Tuesday, May 1, 2018 Pfizer CEO Ian Read contends that the company's pipeline is strong enough to fuel growth. In other words, don't look for a "transformative" deal.
Uh-oh, Xtandi. J&J nabbed an early approval for Erleada by Tracy Staton Wednesday, February 14, 2018 With an early approval for its new drug Erleada, J&J just got a head start over Pfizer and Astellas in nonmetastatic prostate cancer.
Xtandi, apalutamide up for head-to-head fight in prostate cancer by Tracy Staton Tuesday, February 6, 2018 Pfizer, Astellas and J&J envision a wide-open field for patients whose prostate cancer hasn't spread. But there's a high-stakes market scrum ahead.
J&J's blockbuster Zytiga faces 2018 generic threat by Eric Sagonowsky Thursday, January 18, 2018 Johnson & Johnson's prostate cancer drug Zytiga lost a key patent challenge that clears the way for cheap copycats later this year.
Astellas innovation contest yields creative cancer solutions by Beth Snyder Bulik Monday, October 30, 2017 Astellas Oncology's C3 competition featured an AI-powered companion robot and a healthcare professionals’ app to facilitate diagnosis and treatment.
It's time to force lower prices on Biogen MS drug: lawmaker by Eric Sagonowsky Friday, September 29, 2017 Rep. Elijah Cummings, D-Md., is urging President Trump to press for lower prices on Biogen's multiple sclerosis drug Zinbryta.
Astellas, Pfizer eye bigger Xtandi market as key trial scores by Tracy Staton Thursday, September 14, 2017 After Johnson & Johnson's Zytiga put up notable prostate cancer data, Astellas and Pfizer needed a win for their medicine Xtandi. Now they have one.
FiercePharmaAsia—GSK, Pfizer-Astellas, Daiichi Sankyo by Angus Liu Friday, August 4, 2017 GSK will close its Shanghai neuroscience R&D hub, Pfizer and Astellas stopped Xtandi's breast cancer study and more.
